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In Pharmacracy, Thomas Szasz (2001) writes against the appropriation of medicine as a tool of politics. 
Critical awareness should be fostered against all forms of medicalization and against state control of 
health. In Pharmocracy, William Faloon (2011) argues that the US healthcare market suffers from 
inflated prices because the FDA approval system is inefficient and needlessly restrictive. A radically free-
market approach to pharmaceutical regulation and pricing would, he contends, lead to better health 
outcomes overall. In turn, Kaushik Sunder Rajan's Pharmocracy (2017) "coins" the same term to argue 
that multinational pharmaceutical companies should be prevented from establishing "hegemony": 
"Pharmocracy is a term I coin to refer to the global regime of hegemony of the multinational 
pharmaceutical industry" (p. 6). The "appropriation by health by capital" (p. 7) should be stopped. The 
state should not retreat, instead he wants "democratic politics to seize the state" (p. 242; which "state" is 
not quite clear).  
 
Despite the general subtitle ("value, politics, and knowledge in global biomedicine"), the book is focused 
on India, the world's largest democracy and one of the world's largest producers of generic medications. 
Sunder Rajan's rephrasing of "pharmocracy" is a critique of multinational companies (MNCs) trying to 
establish market hegemony in India. Pharmocracy is less an examination of political processes than a 
critique of monopoly capitalism. The great monopolists here are multinational pharmaceutical 
companies. By "multinational," Sunder Rajan does not mean any company that operates in several 
countries with strategies for global market reach, but only companies based in "Euro-America." MNCs 
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that are headquartered in India are not considered multinational. This is in line with how the term 
"multinationals" is popularly used, yet it sits oddly with the fact that most of the big Indian 
pharmaceutical companies have also gone "multinational" in the past decade: Ranbaxy, DRL, Lupin, and 
Cadila have all expanded far beyond India. According to Sunder Rajan, Indian pharmaceutical companies 
exemplify a different logic of capital altogether, one that is not focused on monopoly but on a 
"postcolonial nationalist free market" (p. 154).  
 
Sunder Rajan holds that the Euro-American MNCs' "end game" (p. 158) is eliminating all competitors 
within a particular market. Securing patents is only a means to an end. However, it is quite clear that 
"monopoly" is not the final goal either, but profits and shareholder value. Monopolies secured through 
patents are just one means to maximize profits, even in Euro-American markets. Recent high-profile 
controversies, such as Turing Pharmaceuticals' price hike of Daraprim (a generic drug), show that pricing 
can be greedy without hegemony or patents (Deangelis 2016). Sunder Rajan discusses the capitalist 
appropriation of health as if discovering a profit motive in a for-profit industry was a radical insight. 
Striving for "monopoly" through patents is also hardly a new trait of the pharmaceuticals industry, yet 
the book does not deal in depth with changing legal, political, and regulatory opportunities for companies 
to be able to establish monopolies.  
 
Sunder Rajan has conducted a number of interviews for this book, yet most of the evidence for his two 
case studies (a clinical trial for a HPV vaccine and Novartis' attempt to get a patent for its anticancer drug 
Glivec) comes from published scholarship and grey literature, such as court documents.  
 
The HPV vaccine story on Merck's Gardasil has already been featured widely, both in popular news 
media as well as in major science journals such as The Lancet, Science, and Nature (e.g., Larson, Brocard 
& Garrett 2010; Bagla 2013; Kumar & Butler 2013). However, Sunder Rajan's sources are not 
sufficiently referenced in the book. The vaccine trial story, while noteworthy as a study in how a clinical 
trial can fail, does not illustrate the "pharmocracy" argument well. What emerges is not the hegemonic 
rule of multinational companies in India, but a messy implementation of existing standards and, at worst, 
an attempt by MNCs to get their drugs inserted into public health programs. Sunder Rajan repeatedly 
insists that there was a "scandalous" misconduct in the vaccine trial, leading to the death of a number of 
participants, but then deflates his allegations by saying that no clear links between vaccines and these 




The Glivec story, which takes up two full chapters, has also been told before. That Novartis' court case 
for a Glivec patent in India was about anti-evergreening provisions in the Indian patent law (Section 3d), 
or that Novartis' goal was not to profit from Glivec sales in India but to protect its extremely lucrative 
sales in Europe and North America, has all been said a while ago (Ecks 2008). An interview with an 
Indian hematologist adds details to how Novartis' Glivec Patient Access Program (GIPAP) was 
implemented, but confirms what we already know about the Glivec case.  
 
It is not without irony that Pharmocracy attacks corporations for making existing products look 
innovative in order to win market hegemony. 
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